PMN ProMIS Neurosciences Inc. - Common Shares

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$14.93
Price · Aug 19, 2026
Fundamentals as of Aug 13, 2026

PMN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$14.93
Market Cap
$32M
P/E (TTM)
-0.7
EPS (TTM)
$-22.61
Revenue (TTM)
Div Yield
ROE
4840.3%
Debt/Equity
52W Range
$0 – $27

PMN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income
EPS $-22.61
5-point trend, -1237.9%
2021-12-31 2025-12-31
Free Cash Flow
Margins

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
PMN
Peer Median
P/E (TTM)
4-point trend, +83.2%
-0.7
P/B
3-point trend, -301.9%
-25.5
2.3

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
PMN
Peer Median
ROA
3-point trend, -119.8%
-282.8%
-41.8%
ROE
3-point trend, +2024.8%
4840.3%
-54.1%

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
PMN
Peer Median
Current Ratio
3-point trend, -39.5%
0.9
12.6
Quick Ratio
3-point trend, -56.3%
0.6

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
PMN
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
PMN
Peer Median
EPS (Diluted)
5-point trend, -1237.9%
$-22.61

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
PMN
Peer Median

PMN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 12 analysts
  • Strong Buy 2 16.7%
  • Buy 9 75.0%
  • Hold 1 8.3%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

7 analysts · 2026-08-14
Median target $35.52 +137.9%
Mean target $39.81 +166.6%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
-0.42%
Period EPS Actual EPS Est Surprise
June 30, 2026 $-1.28 $-1.39 0.11%
March 31, 2026 $-1.26 $-1.49 0.23%
Dec. 31, 2025 $-6.57 $-4.93 -1.6%
Sept. 30, 2025 $-6.00 $-6.14 0.14%
June 30, 2025 $-7.25 $-4.42 -2.8%
March 31, 2025 $-5.25 $-3.03 -2.2%
Dec. 31, 2024 $-0.25 $-3.54 3.3%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
PMN $15M -0.3 4840.3%
ZYME $1.97B -24.4 38.9% -76.6% -26.9%
ACOG $141M -5.5 -202.2% -43.8%
ENGN
XENE $3.59B -10.3 -4612.1% -56.9%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 12
Annual Income Statement data for PMN
Metric Trend 20252024202320222021
R&D Expense 5-point trend, +621.3% $33M $11M $8M $16M $5M
SG&A Expense 5-point trend, +85.3% $7M $6M $6M $7M $4M
Operating Expenses 5-point trend, +384.5% $40M $17M $14M $23M $8M
Operating Income 5-point trend, -384.5% $-40M $-17M $-14M $-23M $-8M
Other Non-op 5-point trend, +3328.4% $442.6K $626.2K $384.9K $115.5K $12.9K
Income Tax Flat — no change across 3 periods · $0 $0 $0 ·
Net Income 5-point trend, -305.7% $-40M $3M $-13M $-18M $-10M
EPS (Basic) 5-point trend, -1237.9% $-22.61 $2.68 $-1.07 $-2.41 $-1.69
EPS (Diluted) 5-point trend, -1237.9% $-22.61 $2.63 $-1.07 $-2.41 $-1.69
Shares (Basic) 5-point trend, -69.6% 1,756,844 1,036,799 12,292,707 7,502,609 5,785,617
Shares (Diluted) 5-point trend, -69.6% 1,756,844 1,058,469 12,292,707 7,502,609 5,785,617
EBITDA 3-point trend, -181.6% $-40M $-17M $-14M · ·
Balance Sheet 21
Annual Balance Sheet data for PMN
Metric Trend 20252024202320222021
Cash & Equivalents 5-point trend, -63.9% $6M $13M $13M $6M $17M
Short-term Investments 5-point trend, +1.5% $33.8K $33.1K $32.4K $31.0K $33.2K
Prepaid Expense 5-point trend, +311.2% $3M $6M $988.6K $996.7K $737.3K
Current Assets 5-point trend, -48.2% $9M $19M $14M $7M $18M
PP&E (Net) 2-point trend, -93.1% · · · $321 $4.7K
PP&E (Gross) 2-point trend, -4.4% · · · $80.3K $84.1K
Accum. Depreciation 2-point trend, +0.8% · · · $80.0K $79.4K
Intangibles 2-point trend, -24.5% · · · $20.8K $27.6K
Total Assets 5-point trend, -48.3% $9M $19M $14M $7M $18M
Accounts Payable 5-point trend, +521.9% $3M $2M $8M $3M $409.0K
Accrued Liabilities 5-point trend, +1412.9% $8M $481.0K $2M $3M $520.1K
Current Liabilities 5-point trend, +1020.7% $10M $2M $9M $6M $929.1K
Total Liabilities 5-point trend, -13.6% $10M $2M $10M $8M $12M
Long-term Debt 2-point trend, -100.0% · · $0 · $4M
Common Stock · · · · $0
Paid-in Capital 5-point trend, +90.4% $130M $108M $98M $79M $68M
Retained Earnings 5-point trend, -109.7% $-130M $-91M $-93M $-80M $-62M
AOCI 5-point trend, -97.5% $-371.2K $-371.2K $-371.2K $-195.4K $-187.9K
Stockholders' Equity 5-point trend, -122.2% $-1M $16M $4M $-1M $6M
Liabilities + Equity 5-point trend, -48.3% $9M $19M $14M $7M $18M
Shares Outstanding 5-point trend, -70.1% 2,152,397 1,307,520 18,885,254 8,579,284 7,195,529
Cash Flow 9
Annual Cash Flow data for PMN
Metric Trend 20252024202320222021
Stock-based Comp 5-point trend, +66.3% $857.6K $825.8K $271.5K $487.6K $515.6K
Amort. of Intangibles 3-point trend, +297.0% · · $20.8K $5.1K $5.2K
Operating Cash Flow 5-point trend, -202.2% $-28M $-27M $-11M $-17M $-9M
CapEx 2-point trend, -67.2% · · · $2.0K $6.0K
Investing Cash Flow 5-point trend, -100.7% $-702 $-693 $-1.3K $-2.0K $94.6K
Stock Issued 4-point trend, -95.5% $708.5K $190.3K · $5M $16M
Net Stock Activity 2-point trend, +272.3% $708.5K $190.3K · · ·
Financing Cash Flow 5-point trend, -17.9% $21M $28M $18M $6M $26M
Net Change in Cash 5-point trend, -144.5% $-7M $693.0K $7M $-11M $16M
Profitability 2
Annual Profitability data for PMN
Metric Trend 20252024202320222021
ROA 3-point trend, -119.8% -282.8% 17.1% -128.6% · ·
ROE 3-point trend, +2024.8% 4840.3% 23.4% -251.5% · ·
Liquidity & Solvency 2
Annual Liquidity & Solvency data for PMN
Metric Trend 20252024202320222021
Current Ratio 3-point trend, -39.5% 0.9 8.5 1.5 · ·
Quick Ratio 3-point trend, -56.3% 0.6 6.0 1.4 · ·
Per Share 4
Annual Per Share data for PMN
Metric Trend 20252024202320222021
Book Value / Share 3-point trend, -394.3% $-0.58 $0.50 $0.20 · ·
Cash Flow / Share 3-point trend, -1714.4% $-16.01 $-1.03 $-0.88 · ·
Cash / Share 3-point trend, +326.0% $2.84 $0.41 $0.67 · ·
EPS (TTM) 4-point trend, -838.2% $-22.61 $2.63 $-1.07 $-2.41 ·
Valuation (TTM) 7
Annual Valuation (TTM) data for PMN
Metric Trend 20252024202320222021
Net Income TTM 4-point trend, -119.9% $-40M $3M $-13M $-18M ·
Market Cap 3-point trend, -32.3% $15M $31M $22M · ·
P/E 4-point trend, +83.2% -0.3 0.4 -1.1 -1.8 ·
P/B 3-point trend, -301.9% -11.7 1.9 5.8 · ·
P / Tangible Book 2-point trend, -67.4% · 1.9 5.8 · ·
P / Cash Flow 3-point trend, +73.9% -0.5 -1.1 -2.0 · ·
Earnings Yield 4-point trend, -496.1% -331.0% 276.8% -93.0% -55.5% ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2025-12-312024-12-312023-12-312022-12-312021-12-31
Net Income $-40M$3M$-13M$-18M$-10M
Diluted EPS $-22.61$2.63$-1.07$-2.41$-1.69
Balance Sheet
2025-12-312024-12-312023-12-312022-12-312021-12-31
Current Ratio 0.98.51.5
Quick Ratio 0.66.01.4

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 29 filers · $83.8M total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
4 (-14 vs prior Q) 2 (0 vs prior Q) 7 (+5 vs prior Q) 5 (+1 vs prior Q) -1.0M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
JANUS HENDERSON GROUP PLC $16,418,014 1,292,757 19.60% Shares
Deep Track Capital, LP $10,997,220 835,655 13.13% Shares
WELLINGTON MANAGEMENT GROUP LLP $9,164,334 696,378 10.94% Shares
Ally Bridge Group (NY) LLC $8,163,398 620,319 9.75% Shares
Trails Edge Capital Partners, LP $7,331,475 557,103 8.75% Shares
Woodline Partners LP $5,815,548 441,911 6.94% Shares
Yu Fan $4,339,642 329,760 5.18% Shares
SPHERA FUNDS MANAGEMENT LTD. $4,284,784 325,591 5.12% Shares
Squadron Capital Management LLC $4,276,697 324,977 5.11% Shares
Ikarian Capital, LLC $2,697,801 205,000 3.22% Shares
AMERIPRISE FINANCIAL INC $2,443,812 185,700 2.92% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $2,161,859 164,275 2.58% Shares
683 Capital Management, LLC $1,250,200 95,000 1.49% Shares
ADAR1 Capital Management, LLC $1,221,906 92,850 1.46% Shares
GREAT POINT PARTNERS LLC $1,133,734 86,150 1.35% Shares
BOOTHBAY FUND MANAGEMENT, LLC $816,946 62,078 0.98% Shares
MILLENNIUM MANAGEMENT LLC $737,552 56,045 0.88% Shares
BANK OF MONTREAL /CAN/ $149,642 11,371 0.18% Shares
Seven Fleet Capital Management LP $139,496 10,600 0.17% Shares
MORGAN STANLEY $99,476 7,559 0.12% Shares
Allostery Investments LP $76,303 155,720 0.09% Shares
JNB Advisors LLC $25,561 52,833 0.03% Shares
OSAIC HOLDINGS, INC. $4,737 360 0.01% Shares
ROYAL BANK OF CANADA $3,000 218 0.00% Shares
Steward Partners Investment Advisory, LLC $1,237 94 0.00% Shares
Federation des caisses Desjardins du Quebec $131 10 0.00% Shares
TD Waterhouse Canada Inc. $66 5 0.00% Shares
Caitong International Asset Management Co., Ltd $39 3 0.00% Shares
UBS Group AG $13 1 0.00% Shares

Company insiders 18 insiders · 7 officers · 10 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Neil K Warma Chief Executive Officer May 20, 2026 A 6,183 0 0 $0
Gail M Farfel Chief Executive Officer Aug. 23, 2023 A 55,192 0 0 $0
Daniel E. Geffken Chief Financial Officer Oct. 26, 2023 A 0 0 $0
Gavin T. Malenfant Chief Operating Officer Oct. 26, 2023 A 2,660 0 0 $0
Neil Cashman Chief Scientific Officer May 20, 2026 A 4,122 0 0 $0
Max A. Milbury Principal Accounting Officer May 20, 2026 A 8,409 0 0 $0
Larry Douglas Altstiel Chief Medical Officer Nov. 18, 2024 A 0 0 $0
Slanix Paul Alex Director May 20, 2026 A 0 0 $0
Eugene Williams Director May 20, 2026 A 12,397 4 0 $141,220
Madge K. Shafmaster Director May 20, 2026 A 208,333 0 0 $0
Josh Mandel-Brehm Director May 20, 2026 A 0 0 $0
William W Wyman Director May 20, 2026 A 0 0 $0
Patrick D. Kirwin Director April 22, 2026 P 4,653 1 0 $45,320
Jeremy M. Sclar 2012 Irrevocable Family Trust 10% owner July 29, 2025 P 3,710,459 0 0 $0
Jeremy M. Sclar 10% owner July 29, 2025 P 3,710,459 0 0 $0
Johanne Kaplan Aug. 5, 2026 P 6,221 2 0 $55,329
Title 19 Promis July 25, 2025 X 2,435,029 0 0 $0
Michael S Gordon July 25, 2025 X 0 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 1 position

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
ABG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited, Ally Bridge Group Global Life Science Capital Partners V, L.P., ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, ABG V-SIV X Limited, Fan Yu ×3 filings Feb. 5, 2026 17.00% Amendment SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.